GlassScriptPhysician profile
Syed M Kazmi
NPI 1578810370
$7,100.68
in general payments reported to CMS, 2019-2025
23 companies · $4,367 in 2025
The $4,367 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2023: $113 · 2024: $2,458 · 2025: $4,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,240 · Food and Beverage: $604 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,240.00 |
| Food and Beverage | $603.51 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $6,522.49 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $141.60 | 2019 | |
| Delcath Systems | $122.10 | 2025 | Hepzato Kit |
| Janssen Biotech, INC. | $102.23 | 2025 | Talvey, Tecvayli, Rybrevant |
| Pharmacyclics LLC, An Abbvie Company | $95.00 | 2023 | Imbruvica |
| Axsome Therapeutics, INC. | $34.76 | 2025 | Auvelity |
| Beone Medicines USA, INC. | $28.61 | 2025 | Tevimbra |
| Astellas Pharma US INC | $20.57 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.37 | 2023 | |
| Tempus Ai, INC | $14.95 | 2025 | Xt Cdx |
13 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Kazmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.